[시장보고서]세계의 임상시험 서비스 시장 : 유형별, 단계별, 치료법별, 모달리티별, 딜리버리 모델별

세계의 임상시험 서비스 시장 : 유형별, 단계별, 치료법별, 모달리티별, 딜리버리 모델별 - 예측(-2030년)

Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030

상품코드 : 1682826 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 03월

페이지 정보 : 영문 522 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 6,967,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,359,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,471,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,075,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계 임상시험 서비스 시장 규모는 2025년 665억 9,000만 달러에서 2030년 1,018억 6,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 8.9%의 성장률을 보일 것으로 예상됩니다.

제약, 바이오, 의료기기 기업들이 임상 연구 활동을 CRO(임상시험수탁기관)에 아웃소싱하는 사례가 증가함에 따라 CRO가 제공하는 기능적 서비스 제공업체(FSP), 하이브리드 서비스 제공 모델과 같은 유연한 서비스 모델이 시장을 확대하고 있습니다. 유연한 서비스 모델은 기업이 중요한 업무를 통제하면서 비용 관리를 가능하게 합니다. 분산형 모델, 웨어러블 기기, 디지털 플랫폼을 활용하여 환자 참여와 유지를 강화하는 환자 중심 임상시험에 대한 수요가 증가하고 있으며, AI와 리얼월드 데이터(RWD) 등의 기술 발전으로 임상시험의 효율성, 시설 선정, 환자 모집이 최적화되고 있습니다. 최적화되고 있습니다. 개인화된 의료와 정밀의료에 대한 수요 증가로 표적치료에 초점을 맞춘 임상시험이 증가하고 있으며, CRO는 복잡한 임상시험 설계를 지원해야 합니다. 규제 기관은 소아 임상시험을 중시하고 있으며, CRO는 전문 지식을 습득할 필요가 있습니다. 또한, 임상시험의 다양성을 장려하는 FDA의 가이드라인은 CRO가 환자 모집을 확대하고 더 폭넓은 대표성을 확보할 수 있는 기회를 창출하고 있습니다. 세포치료, 유전자치료, 생물학적 제제, RNA를 이용한 치료 등 신약 파이프라인 증가는 전문적인 임상연구 서비스의 필요성을 더욱 높이고 있습니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2024-2030년
단위	10억 달러
부문	단계, 서비스 유형, 치료 영역, 용도, 최종 사용자, 지역
대상 지역	북미 유럽, 아시아태평양, 기타 지역

"치료 영역별로는 종양 치료 영역이 예측 기간 동안 임상시험 서비스 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다."

2024년 임상시험 서비스 시장 중 종양 치료 분야가 치료 분야별로 가장 큰 시장을 차지했습니다. 전 세계 수많은 암 환자와 새로운 치료법에 대한 필요성이 이 치료 영역의 큰 점유율을 뒷받침하고 있습니다. 암 연구는 복잡하고 표적치료제, 면역치료제, 병용요법의 시험이 필요합니다. 규제 기관은 암 치료제의 승인을 우선시하기 때문에 이 분야의 임상시험이 증가하고 있습니다. 또한, 정밀의료와 바이오마커 연구의 발전으로 암 분야 임상시험이 증가하고 있으며, 환자 모집 및 임상시험 관리 전문 지식이 요구되고 있습니다. 제약회사, 정부기관, 환자단체의 강력한 투자는 암 연구를 더욱 촉진하고 있으며, 암 분야는 임상시험의 주요 부문이 되고 있습니다.

"최종 사용자별로는 제약 및 바이오 제약 기업이 예측 기간 동안 임상시험 서비스 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다."

임상시험을 자체적으로 수행하기 위해서는 인프라, 인력, 규제 준수에 많은 투자가 필요하기 때문에 임상시험의 복잡성이 증가함에 따라 아웃소싱이 보다 비용 효율적이고 효율적인 선택이 될 수 있습니다. 임상시험 설계, 환자 모집, 규제 준수, 데이터 관리 등의 전문성을 활용하여 의약품 개발을 가속화할 수 있습니다. 또한, R&D 파이프라인의 확대와 정밀의료에 대한 관심이 높아짐에 따라 제약사들은 임상 서비스 및 임상시험의 아웃소싱을 통해 업무 부담을 최소화하고 리소스를 최적화하고 있습니다.

세계의 임상시험 서비스 시장에 대해 조사 분석했으며, 주요 성장 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.

임상시험 서비스 시장 기업에 있어서 매력적인 기회
북미의 임상시험 서비스 시장 : 모달리티별, 국가별(2024년)
임상시험 서비스 시장 : 서비스 유형별(2025년/2030년)
임상시험 서비스 시장 : 최종사용자별(2024년)
임상시험 서비스 시장 : 국가별

제5장 시장 개요

서론
시장 역학
- 성장 촉진요인
- 기회
- 과제
시장 동향
고객의 비즈니스에 영향을 미치는 동향/혼란
가격 분석
- 가격 분석 : 주요 기업별(정성)
- 참고 가격 분석 : 단계별(2024년)
- 참고 가격 분석 : 치료 영역별(2024년)
밸류체인 분석
생태계 분석
투자와 자금조달 시나리오
기술 분석
- 주요 기술
- 보완 기술
주요 컨퍼런스 및 이벤트(2025년-2026년)
규제 상황
- 규제 구조
- 규제기관, 정부기관, 기타 조직
Porter의 Five Forces 분석
주요 이해관계자와 구입 기준
임상시험 서비스 시장에 대한 AI/생성형 AI의 영향
- 서론
- 임상시험 시장의 잠재력
- AI 이용 사례
- AI를 도입한 주요 기업
- 임상시험 에코시스템 생성형 AI의 미래

제6장 임상시험 서비스 시장 : 서비스 유형별

서론
임상시험 관리·모니터링
연구실 서비스
임상시험 데이터 관리 서비스
임상시험 공급 및 물류 서비스
컨설팅
환자 모집 및 유지
메디컬 라이팅
안전성 및 약물 감시
기타 서비스 유형

제7장 임상시험 서비스 시장 : 단계별

서론
단계 III
단계 II
단계 I
단계 IV

제8장 임상시험 서비스 시장 : 모달리티별

서론
소분자
생물학적 제제
의료기기·IVD

제9장 임상시험 서비스 시장 : 치료 영역별

서론
종양
신경
호흡기질환
대사질환/내분비
심혈관계 장애
피부과
위장 질환
면역 질환
감염증
정신
안과
혈액
비뇨생식기 및 부인과
기타 치료 영역

제10장 임상시험 서비스 시장 : 딜리버리 모델별

서론
풀 서비스 아웃소싱(FSO) 모델
기능적 서비스 제공업체(FSP) 모델
하이브리드 모델

제11장 임상시험 서비스 시장 : 임상시험 디자인별

서론
개입
관찰

제12장 임상시험 서비스 시장 : 최종사용자별

서론
제약 및 바이오의약품 기업
의료기기 기업
학술기관

제13장 임상시험 서비스 시장 : 지역별

서론
북미
- 미국
- 캐나다
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- 기타 아시아태평양
라틴아메리카
- 브라질
- 멕시코
- 기타 라틴아메리카
중동
- GCC 국가
- 기타 중동
- 아프리카

제14장 경쟁 구도

개요
주요 시장 진출기업의 전략/강점
매출 분석
시장 점유율 분석(2024년)
기업 평가 매트릭스 : 주요 기업(2024년)
기업 평가 매트릭스 : 스타트업/중소기업(2024년)
기업 평가와 재무 지표
브랜드/서비스 비교
경쟁 시나리오

제15장 기업 개요

주요 기업
- IQVIA INC.
- ICON PLC
- THERMO FISHER SCIENTIFIC INC.
- FORTREA
- SYNEOS HEALTH
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- MEDPACE
- WUXI APPTEC
- FRONTAGE LABS
- PHARMARON
- TIGERMED
- SGS SOCIETE GENERALE DE SURVEILLANCE SA
- EUROFINS SCIENTIFIC
- LINICAL
- PAREXEL INTERNATIONAL CORPORATION
기타 기업
- WORLDWIDE CLINICAL TRIALS
- PROPHARMA
- NOVOTECH
- PSI
- ALLUCENT
- PREMIER RESEARCH
- CAIDYA
- ERGOMED GROUP
- CLARIO
- PRECISION MEDICINE GROUP, LLC.
- ADVANCED CLINICAL
- EPS HOLDINGS, INC.
- GUIRES INC.(PEPGRA)
- KCR S.A.

제16장 부록

LSH

영문 목차

영문목차

The global clinical trial services market is projected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025, growing at a CAGR of 8.9% during the forecast period. This market is expanding as pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing their clinical research activities to Contract Research Organizations (CROs). Flexible service models, such as Functional Service Provider (FSP) and hybrid service delivery models, offered by CROs enable cost management while allowing companies to retain control over critical operations. There is a growing demand for patient-centric trials, leveraging decentralized models, wearable devices, and digital platforms to enhance patient participation and retention. Technological advancements, including artificial intelligence (AI) and real-world data (RWD), are optimizing trial efficiency, site selection, and patient recruitment. The rising demand for personalized and precision medicine is driving an increase in clinical studies focused on targeted therapies, requiring CROs to support complex trial designs. Regulatory bodies are emphasizing pediatric clinical trials, requiring CROs to develop specialized expertise. Additionally, FDA guidelines promoting diversity in clinical trials are creating opportunities for CROs to expand patient recruitment and ensure broader representation. The increasing pipeline of new drug modalities, including cell and gene therapies, biologics, and RNA-based treatments, is further driving the need for specialized clinical research services.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Phase, Service Type, Therapeutic Area, Application,End User, and Region
Regions covered	North America, Europe, APAC, RoW

"The oncology therapy area segment held the largest share in the clinical trial services market, by therapy area, during the forecast period"

In 2024, the oncology therapy area held the largest market within the clinical trial services market by therapy area. Factors such as the large number of cancer cases worldwide and the need for new treatments are supporting the large share of this therapy area. Cancer research is complex, requiring trials for targeted therapies, immunotherapies, and combination treatments. Regulatory agencies prioritize cancer drug approvals, leading to more trials in this area. Advances in precision medicine and biomarker research have also increased oncology trials, requiring expertise in patient recruitment and trial management. Strong investments from pharmaceutical companies, government agencies, and patient organizations further drive cancer research, making oncology the leading segment in clinical trials.

"The pharmaceutical & biopharmaceutical companies end user segment held the largest market share in the clinical trials services market, by end user, during the forecast period"

Pharmaceutical and biopharmaceutical companies dominated the clinical trial services end-user/sponsor market during the forecast period. Conducting in-house trials demands substantial investments in infrastructure, personnel, and regulatory compliance, making outsourcing a more cost-effective and efficient alternative as trial complexity increases. Partnering with Contract Research Organizations (CROs) allows these companies to leverage expertise in trial design, patient recruitment, regulatory adherence, and data management, expediting drug development. Additionally, the expanding R&D pipeline and growing focus on precision medicine have led pharmaceutical companies to outsource clinical services and laboratory testing, minimizing operational burdens and optimizing resources.

"Asia Pacific: The fastest growing region in the clinical trial services market"

The Asia Pacific clinical trial services market is projected to register the highest growth rate during the forecast period. This high growth is attributed to its large patient pool, high incidence of chronic and infectious diseases, and growing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly shifting manufacturing and clinical research to the region to benefit from cost advantages, regulatory improvements, and better patient retention in trials. Additionally, government support and increasing investments in clinical research have further driven the outsourcing of clinical trial activities to APAC, contributing to its strong market growth.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

IQVIA Inc. (US)
Thermo Fisher Scientific Inc. (US)
Fortrea (US)
ICON Plc (Ireland)
Syneos Health (US)
Laboratory Corporation of America Holdings (US)
Medpace (US)
Wuxi AppTec (China)
Frontage Labs (US)
Pharmaron (US)
Tigermed (China)
SGS Societe Generale De Surveillance SA. (Switzerland)
Eurofins Scientific (Luxembourg)
Linical (Japan)
Parexel International Corporation (US)
Worldwide Clinical Trials (US)
Novotech (Australia)
PSI (Switzerland)
Allucent (US)
Premier Research (US)
Clario (US)
KCR S.A. (US)
Rho, Inc. (US)
Advanced Clinical (US)

Research Coverage:

This report provides a detailed picture of the global clinical trial service market. It aims to estimate the size and future growth potential of the market across different segments such as the service type, therapy area, phase, delivery model, modality, end user/sponsor, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new service launches, mergers and acquisitions, and recent developments associated with the clinical trial services market. Competitive analysis of upcoming startups in the clinical trial services market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall clinical trial services market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing focus on patient-centric trials (DCTs), increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing, rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities, service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) and technological integrations), opportunities (Increased focus on pediatric clinical trials, regulatory requirement for increasing diversity in clinical trials, growing role of real-world evidence in drug approvals, expanding drug modalities (such as CGT, ADCs, Bispecific Abs) in clinical trials), and challenges (Cybersecurity or intellectual property concerns, and challenge of patient retention) influencing the growth of the clinical trial services market.
Service Development/Innovation: Detailed insights on upcoming technologies, and new service launches in the clinical trial services market
Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial services market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the clinical trial services market

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 REGIONAL SCOPE
- 1.3.3 INCLUSIONS AND EXCLUSIONS
- 1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
2.2 GLOBAL MARKET ESTIMATION
- 2.2.1 MARKET ESTIMATION METHODOLOGY
  - 2.2.1.1 Insights from primary experts
- 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET
4.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY (2024)
4.3 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030)
4.4 CLINICAL TRIAL SERVICES MARKET, BY END USER (2024)
4.5 CLINICAL TRIAL SERVICES MARKET, BY COUNTRY

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Increasing focus on patient-centric trials (DCTs)
  - 5.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing
  - 5.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities
  - 5.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid)
  - 5.2.1.5 Technological integrations
- 5.2.2 OPPORTUNITIES
  - 5.2.2.1 Increased focus on pediatric clinical trials
  - 5.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials
  - 5.2.2.3 Growing role of real-world evidence in drug approvals
  - 5.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials
- 5.2.3 CHALLENGES
  - 5.2.3.1 Cybersecurity or intellectual property concerns
  - 5.2.3.2 Challenge of patient retention
  - 5.2.3.3 Growing market competition
5.3 MARKET TRENDS
- 5.3.1 IN SILICO CLINICAL TRIALS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.5 PRICING ANALYSIS
- 5.5.1 PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE)
- 5.5.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2024
- 5.5.3 INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
  - 5.9.1.1 Clinical trial management system (CTMS)
  - 5.9.1.2 Electronic data capture (EDC) systems
  - 5.9.1.3 Randomization and trial supply management (RTSM)
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
  - 5.9.2.1 Telemedicine and wearable devices
  - 5.9.2.2 AI and ML integration
5.10 KEY CONFERENCES AND EVENTS, 2025-2026
5.11 REGULATORY LANDSCAPE
- 5.11.1 REGULATORY FRAMEWORK
  - 5.11.1.1 North America
  - 5.11.1.2 Europe
  - 5.11.1.3 Asia Pacific
  - 5.11.1.4 RoW
- 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 THREAT OF NEW ENTRANTS
- 5.12.2 THREAT OF SUBSTITUTES
- 5.12.3 BARGAINING POWER OF SUPPLIERS
- 5.12.4 BARGAINING POWER OF BUYERS
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.13.2 BUYING CRITERIA
5.14 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET
- 5.14.1 INTRODUCTION
- 5.14.2 MARKET POTENTIAL FOR CLINICAL TRIALS
- 5.14.3 AI USE CASES
- 5.14.4 KEY COMPANIES IMPLEMENTING AI
- 5.14.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM

6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE

6.1 INTRODUCTION
6.2 CLINICAL TRIAL MANAGEMENT & MONITORING
- 6.2.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH
6.3 LABORATORY SERVICES
- 6.3.1 ANALYTICAL TESTING SERVICES
  - 6.3.1.1 Increasing demand for analytical testing for drug development to drive market
- 6.3.2 BIOANALYTICAL TESTING SERVICES
  - 6.3.2.1 Rising focus on biologics in advanced therapies to drive market
6.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES
- 6.4.1 BIOSTATISTICS
  - 6.4.1.1 Integration of real-world data (RWD) into statistical analysis to support market growth
- 6.4.2 OTHER DATA MANAGEMENT SERVICES
6.5 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
- 6.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET
6.6 CONSULTING
- 6.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET
6.7 PATIENT RECRUITMENT & RETENTION
- 6.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH
6.8 MEDICAL WRITING
- 6.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET
6.9 SAFETY & PHARMACOVIGILANCE
- 6.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH
6.10 OTHER SERVICE TYPES

7 CLINICAL TRIAL SERVICES MARKET, BY PHASE

7.1 INTRODUCTION
7.2 PHASE III
- 7.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING
7.3 PHASE II
- 7.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS
7.4 PHASE I
- 7.4.1 DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH
7.5 PHASE IV
- 7.5.1 SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH

8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY

8.1 INTRODUCTION
8.2 SMALL MOLECULES
- 8.2.1 EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH
8.3 BIOLOGICS
- 8.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND
8.4 MEDICAL DEVICES & IVD
- 8.4.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND

9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA

9.1 INTRODUCTION
9.2 ONCOLOGY
- 9.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET
9.3 NEUROLOGY
- 9.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET
9.4 RESPIRATORY DISORDERS
- 9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
9.5 METABOLIC DISORDERS/ENDOCRINOLOGY
- 9.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH
9.6 CARDIOVASCULAR SYSTEM DISORDERS
- 9.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET
9.7 DERMATOLOGY
- 9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH
9.8 GASTROINTESTINAL DISEASES
- 9.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET
9.9 IMMUNOLOGICAL DISORDERS
- 9.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH
9.10 INFECTIOUS DISEASES
- 9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET
9.11 PSYCHIATRY
- 9.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH
9.12 OPHTHALMOLOGY
- 9.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
9.13 HEMATOLOGY
- 9.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
9.14 GENITOURINARY & WOMEN'S HEALTH
- 9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
9.15 OTHER THERAPEUTIC AREAS

10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL

10.1 INTRODUCTION
10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
- 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
- 10.3.1 GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
10.4 HYBRID MODEL
- 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH

11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN

11.1 INTRODUCTION
11.2 INTERVENTIONAL
- 11.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET
11.3 OBSERVATIONAL
- 11.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH

12 CLINICAL TRIAL SERVICES MARKET, BY END USER

12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 12.2.1 INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
12.3 MEDICAL DEVICE COMPANIES
- 12.3.1 RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET
12.4 ACADEMIC INSTITUTES
- 12.4.1 RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA TO DRIVE MARKET

13 CLINICAL TRIAL SERVICES MARKET, BY REGION

13.1 INTRODUCTION
13.2 NORTH AMERICA
- 13.2.1 US
  - 13.2.1.1 Presence of well-established CROs to drive market
- 13.2.2 CANADA
  - 13.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market
13.3 EUROPE
- 13.3.1 GERMANY
  - 13.3.1.1 Growing R&D spending and favorable government policies to propel market
- 13.3.2 UK
  - 13.3.2.1 Rising collaborations and improved policies to support market
- 13.3.3 FRANCE
  - 13.3.3.1 Government-led support for effective drug research to drive market
- 13.3.4 ITALY
  - 13.3.4.1 Government-led focus on improving clinical trial regulations to drive market
- 13.3.5 SPAIN
  - 13.3.5.1 Rising R&D expenditure to boost market growth
- 13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
- 13.4.1 CHINA
  - 13.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market
- 13.4.2 INDIA
  - 13.4.2.1 Cost-efficient and innovation-driven approach to propel market
- 13.4.3 JAPAN
  - 13.4.3.1 Decline in number of clinical trials to limit market
- 13.4.4 AUSTRALIA
  - 13.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
- 13.4.5 SOUTH KOREA
  - 13.4.5.1 Favorable government initiatives for drug development to drive market
- 13.4.6 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
- 13.5.1 BRAZIL
  - 13.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market
- 13.5.2 MEXICO
  - 13.5.2.1 Increasing investments in pharma R&D to drive market
- 13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST
- 13.6.1 GCC COUNTRIES
  - 13.6.1.1 Saudi Arabia
    - 13.6.1.1.1 Increase in collaborations to drive market
  - 13.6.1.2 UAE
    - 13.6.1.2.1 Growing clinical research activities to drive market
  - 13.6.1.3 Rest of GCC countries
- 13.6.2 REST OF MIDDLE EAST
- 13.6.3 AFRICA
  - 13.6.3.1 Expanding pharmaceutical industry to support market growth

14 COMPETITIVE LANDSCAPE

14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.3 REVENUE ANALYSIS
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 14.5.5.1 Company footprint
  - 14.5.5.2 Region footprint
  - 14.5.5.3 Service type footprint
  - 14.5.5.4 Phase footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  - 14.6.5.1 Detailed list of key startups/SMEs
  - 14.6.5.2 Competitive benchmarking of startups/SMEs
14.7 COMPANY VALUATION AND FINANCIAL METRICS
14.8 BRAND/SERVICE COMPARISON
14.9 COMPETITIVE SCENARIO
- 14.9.1 SERVICE LAUNCHES
- 14.9.2 DEALS
- 14.9.3 EXPANSIONS

15 COMPANY PROFILES

15.1 KEY PLAYERS
- 15.1.1 IQVIA INC.
  - 15.1.1.1 Business overview
  - 15.1.1.2 Services offered
  - 15.1.1.3 Recent developments
    - 15.1.1.3.1 Service launches
    - 15.1.1.3.2 Deals
    - 15.1.1.3.3 Expansions
  - 15.1.1.4 MnM view
    - 15.1.1.4.1 Right to win
    - 15.1.1.4.2 Strategic choices
    - 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 ICON PLC
  - 15.1.2.1 Business overview
  - 15.1.2.2 Services offered
  - 15.1.2.3 Recent developments
    - 15.1.2.3.1 Service launches
    - 15.1.2.3.2 Deals
  - 15.1.2.4 MnM view
    - 15.1.2.4.1 Right to win
    - 15.1.2.4.2 Strategic choices
    - 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 THERMO FISHER SCIENTIFIC INC.
  - 15.1.3.1 Business overview
  - 15.1.3.2 Services offered
  - 15.1.3.3 Recent developments
    - 15.1.3.3.1 Service launches
    - 15.1.3.3.2 Deals
    - 15.1.3.3.3 Expansions
  - 15.1.3.4 MnM view
    - 15.1.3.4.1 Right to win
    - 15.1.3.4.2 Strategic choices
    - 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 FORTREA
  - 15.1.4.1 Business overview
  - 15.1.4.2 Services offered
  - 15.1.4.3 Recent developments
    - 15.1.4.3.1 Service launches
    - 15.1.4.3.2 Deals
    - 15.1.4.3.3 Expansions
  - 15.1.4.4 MnM view
    - 15.1.4.4.1 Right to win
    - 15.1.4.4.2 Strategic choices
    - 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 SYNEOS HEALTH
  - 15.1.5.1 Business overview
  - 15.1.5.2 Services offered
  - 15.1.5.3 Recent developments
    - 15.1.5.3.1 Service launches
    - 15.1.5.3.2 Deals
  - 15.1.5.4 MnM view
    - 15.1.5.4.1 Right to win
    - 15.1.5.4.2 Strategic choices
    - 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
  - 15.1.6.1 Business overview
  - 15.1.6.2 Services offered
  - 15.1.6.3 Recent developments
    - 15.1.6.3.1 Service launches
    - 15.1.6.3.2 Deals
    - 15.1.6.3.3 Expansions
  - 15.1.6.4 MnM view
    - 15.1.6.4.1 Right to win
    - 15.1.6.4.2 Strategic choices
    - 15.1.6.4.3 Weaknesses and competitive threats
- 15.1.7 MEDPACE
  - 15.1.7.1 Business overview
  - 15.1.7.2 Services offered
- 15.1.8 WUXI APPTEC
  - 15.1.8.1 Business overview
  - 15.1.8.2 Services offered
  - 15.1.8.3 Recent developments
    - 15.1.8.3.1 Deals
- 15.1.9 FRONTAGE LABS
  - 15.1.9.1 Business overview
  - 15.1.9.2 Services offered
  - 15.1.9.3 Recent developments
    - 15.1.9.3.1 Deals
    - 15.1.9.3.2 Expansions
- 15.1.10 PHARMARON
  - 15.1.10.1 Business overview
  - 15.1.10.2 Services offered
- 15.1.11 TIGERMED
  - 15.1.11.1 Business overview
  - 15.1.11.2 Services offered
  - 15.1.11.3 Recent developments
    - 15.1.11.3.1 Service approvals
    - 15.1.11.3.2 Deals
- 15.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA
  - 15.1.12.1 Business overview
  - 15.1.12.2 Services offered
- 15.1.13 EUROFINS SCIENTIFIC
  - 15.1.13.1 Business overview
  - 15.1.13.2 Services offered
- 15.1.14 LINICAL
  - 15.1.14.1 Business overview
  - 15.1.14.2 Services offered
  - 15.1.14.3 Recent developments
    - 15.1.14.3.1 Deals
    - 15.1.14.3.2 Expansions
- 15.1.15 PAREXEL INTERNATIONAL CORPORATION
  - 15.1.15.1 Business overview
  - 15.1.15.2 Services offered
  - 15.1.15.3 Recent developments
    - 15.1.15.3.1 Service launches
    - 15.1.15.3.2 Deals
    - 15.1.15.3.3 Expansions
15.2 OTHER PLAYERS
- 15.2.1 WORLDWIDE CLINICAL TRIALS
- 15.2.2 PROPHARMA
- 15.2.3 NOVOTECH
- 15.2.4 PSI
- 15.2.5 ALLUCENT
- 15.2.6 PREMIER RESEARCH
- 15.2.7 CAIDYA
- 15.2.8 ERGOMED GROUP
- 15.2.9 CLARIO
- 15.2.10 PRECISION MEDICINE GROUP, LLC.
- 15.2.11 ADVANCED CLINICAL
- 15.2.12 EPS HOLDINGS, INC.
- 15.2.13 GUIRES INC. (PEPGRA)
- 15.2.14 KCR S.A.

16 APPENDIX

16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS